Trial Profile
Prospective, multi-centric, open-label, two-arm, parallel group, active-control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-017 / MabThera (Ristova) in patients with Non-Hodgkins Lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Reliance Life Sciences
- 25 Feb 2020 Status changed from active, no longer recruiting to completed.
- 12 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2012 New trial record